| |
P E R S P E C T I V E F U T U R E E L D E R L Y
26 September 2005
Projecting The Future Of U.S. Health And Longevity
Two papers address the nation’s
future health
in different ways; both add substance to the debate.
By S. Jay Olshansky
ABSTRACT:
Is the health of the U.S. population improving or getting worse, and
how are health and medical costs influenced by obesity? How will anticipated
advances in the biomedical sciences influence life expectancy and the cost of
health care? The paper by Dana Goldman and colleagues is a daring speculation
on the life-extending effects of possible future technologies—a valuable
exercise given the speed of technological advances. Darius Lakdawalla and colleagues
provide a methodologically solid basis for concluding that not only does obesity
kill, it also takes an alarming toll on health and health care spending at levels
that require immediate intervention.
What will the future of U.S. health and longevity be? This is a question that
scientists, pundits, and authors of science fiction novels have written about
for centuries. Given the inevitable demographic wave of population aging now
approaching the shoreline, estimating its magnitude and impact on the size of
the beneficiary population and health care costs is of critical public policy
importance. Papers in this Health Affairs online collection are focused
squarely on this topic; here I discuss those by Dana Goldman and colleagues
and by Darius Lakdawalla and colleagues.
Goldman and colleagues.
The paper by Goldman and colleagues is an economist’s view of how to model
the future hazards of death and the financial costs of efforts to keep people
alive using hypothetical technologies not yet in existence.1
Think about this for a moment: This is not an easy exercise. First one has to
come up with a list of technologies that do not yet exist but that might, and
then one must estimate the impact these nonexistent technologies could have
on the health and risk of death of today’s younger generation when they
are old enough to use them. To make such estimates, one has to pile one assumption
upon another until what looks like a house of cards has been constructed. Is
the result worth the risk of constructing such fragile models? In this case,
I would have to say that it is.
It is important to remember that this paper was not written as a projection
model intended as a serious attempt to predict the future, but rather as a way
to estimate the effect of hypothetical life-extending technologies on death
rates and health care costs. If this were a genuine attempt to forecast the
future, then the model and assumptions would have had to be extended to include
other forces that could simultaneously increase the risk of death, such as the
reemergence of infectious diseases and the serious obesity epidemic now plaguing
younger generations.
The value of the model developed by Goldman and colleagues is that it provides
readers with conceptual boundaries within which hypothetical life-extending
technologies might influence the extension of life and health care costs. The
microsimulation model used is based on data about Medicare beneficiaries from
a 1992–1999 survey, hypothetically aging this cohort forward using observed
single-year death probabilities from the same survey and then eliciting “consensus
from several panels of distinguished experts” on what new technologies
might be forthcoming and how they might influence death rates. The question
I find myself asking is this: How believable are the results?
The ability of forecasting models to accurately predict the future is evaluated
not on how well they predict the future, because for obvious reasons this cannot
be known until the projection time frame has expired, but on how well they predict
the present from the past. The forecasting models developed by these authors
were never evaluated in this way, so it is not possible to assess their past
performance. Furthermore, the hypothesized effects of nonexistent technologies
on future death rates simply appear as if by magic. For example, the authors
assume that a “mythical compound” (this is the phrase the authors
use to describe this intervention) that extends life by mimicking the life-extending
effect of caloric restriction on other animals will be developed for humans;
it is assumed that the percentage increase in life expectancy from caloric restriction
will be the same for humans as it is now observed for some other species (25
percent); only people age sixty-five and older will take this compound, at a
cost of a dollar per day for thirty years; and it is projected to increase life
expectancy at birth by ten years. All of the gain must come from reductions
in death rates among those age sixty-five and older.
Where do these assumptions come from? The vast literature on caloric restriction
is never referenced, so the casual reader will not know that serious obstacles
remain in developing and applying such findings to humans; contrary to the authors’
assumptions, there is reason to suspect that the life-extending effect observed
in other mammals would not have the same life-extending effect on humans.2
Why would people only age sixty-five and older take the mythical compound? Where
did the cost estimate of a dollar a day come from (this seems rather low for
any life-extending technology)? And how did the authors come up with an estimated
ten-year increase in life expectancy at birth? The lack of answers to these
questions should make any reader skeptical. Similar questions may be raised
about all of the other hypothetical life-extending technologies modeled in this
paper.
If questions about the methodology and assumptions are not enough, the main
issue, as I see it, is the model’s underlying premise that the best way
to peer into the future is to observe and extrapolate from the past—a
methodology that has been popular among mathematical demographers for forecasting
life expectancy.3 This may be a useful approach
for forecasting the weather or cyclical trends in the stock market, but when
it comes to human health and longevity, it makes more sense to try first to
understand the biology of aging and death, the limiting structure of human body
design, and the presence of younger generations that are already facing the
prospect of much higher adult mortality than previous generations have had to
face.4
Lakdawalla and colleagues.
The paper by Lakdawalla and colleagues addresses one of the hottest issues now
being debated in the public health arena: the health effects of obesity.5
Scientists have been debating what methods and assumptions to use when calculating
the number of annual deaths attributable to obesity; the result has been a range
from 112,000 to 300,000.6 Such variation is the
product of relatively minor differences in assumptions rather than differences
in methodology, although in one instance, a clerical error led to an overestimate
of deaths due to obesity.7 However, the public health
message is the same, regardless of which estimate is eventually found to be
closer to the truth: Obesity is harmful. As is always the case with such public
health conclusions, the usual caveat applies that the harmful effects are not
equally distributed in the population.
What Ladkawalla and colleagues have done is put their finger right on the most
important issue to come out of this literature. The bottom-line message in all
of the research on the health effects of obesity is consistent: Not only does
obesity increase the risk of death for most people at most ages, it consistently
leads to a much higher level of disability and disease at all ages. Researchers
can fight internally within scientific journals about the methodological nuances
that lead to varying estimates of obesity-induced deaths. However, the fact
remains that all of these numbers are too high; most of these deaths can be
delayed by encouraging people to adopt healthier lifestyles based on reduced
caloric intake and increased exercise; and the important, definitive take-away
message is that obesity accelerates disease, increases disability, and greatly
increases the cost of medical care.
An article recently published by Edward Gregg and colleagues demonstrated that
the risk of cardiovascular disease (CVD) associated with obesity at all levels
of body mass index (BMI) has declined in recent years.8
Medicine has become more efficient at extending the lives of the obese by treating
some of its complications more effectively, but such “improvements”
are occurring during a time when the prevalence and severity of obesity, especially
among children, continue to worsen. According to Gregg and colleagues, “The
net result of these phenomena may be a population that is, paradoxically, more
obese, diabetic, arthritic, disabled, and medicated, but with lower overall
CVD risk.”9 These findings are now echoed
and confirmed by Lakdawalla and colleagues: Carrying extra weight at BMI levels
of 30 or more might not always kill (although it does so often enough to warrant
intervention), but it consistently leads to a much higher risk of lethal and
disabling health problems. Most important of all, it has now been confirmed
that obesity dramatically increases the number of years lived with disability.
Readers should be aware of the fact that the findings from Lakdawalla and colleagues,
and those of Gregg and colleagues, are based on the prevalence of obesity and
its health effects observed during about the past fifteen years in the United
States. The people sampled in these surveys were born at the beginning and middle
of the twentieth century and exhibited their obesity-induced morbidity and mortality
in the latter part of that century. Future generations will be far different
from those upon whom such estimates are made, and studies of this kind cannot
account for this difference. The prevalence of obesity among today’s younger
generation is much higher than that of previous generations, and young people
today carry much more weight at an earlier age than any preceding generation
has done.10 We have already witnessed the rise
of Type II diabetes among children in many developed countries today—a
severe health problem never seen before 1980.11
My colleagues and I have estimated that in the absence of interventions that
attenuate the obesity epidemic among children, the negative effect of obesity
on the life expectancy of the U.S. population could rise from current levels
of under one year to more than five years within the next half-century.12
This says nothing of the negative effect of today’s childhood obesity
epidemic on the prevalence of disability among cohorts of middle-aged and older
people in the coming decades—which would be expected to rise well beyond
the estimates provided by Lakdawalla and colleagues.
Concluding comments.
Both papers are valuable contributions to the literature for different reasons.
The paper by Goldman and colleagues is useful at one level because the authors
dare to speculate on the life-extending effects of possible future technologies.
This kind of speculation needs to be done to help inform the debate about the
future of human life expectancy, and it is clear that the authors have given
considerable thought to the topic. Although I have problems with many of their
assumptions, the results at least provide a useful frame of reference.
The paper by Lakdawalla and colleagues focuses our attention on the most important
issue in the obesity debate: the observed health and well-being of the population
as measured by trends in health expectancy. Shifting the focus from death to
health is the crystallizing message here, and the authors provide a methodologically
solid basis for concluding that not only does obesity kill, it already takes
an alarming toll on health and health care spending in this country at levels
that require immediate intervention.
NOTES
1. D.P. Goldman et al., “Consequences of Health Trends
and Medical Innovation for the Future Elderly,” Health Affairs,
26 September 2005, content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.r5.
2. L. Demetrius, “Caloric Restriction, Metabolic Rate,
and Entropy,” Journals of Gerontology, Series A: Biological Sciences
and Medical Sciences 59, no. 9 (2004): B902–B915.
3. J. Oeppen and J. Vaupel, “Demography: Broken Limits
to Life Expectancy,” Science 296, no. 5570 (2002): 1029–1031.
4. See B.A. Carnes, S.J. Olshansky, and D. Grahn, “Biological
Evidence for Limits to the Duration of Life,” Biogerontology
4, no. 1 (2003): 31–45; S.J. Olshansky, B.A. Carnes, and R. Butler, “If
Humans Were Built to Last,” Scientific American (May 2003): 94–100;
J.P. Koplan, C.T. Liverman, and V.I. Kraak, eds., Preventing Childhood Obesity:
Health in the Balance (Washington: National Academies Press, 2004); and
C.B. Ebbeling, D.B. Pawlak, and D.S. Ludwig, “Childhood Obesity: Public-Health
Crisis, Common Sense Cure,” Lancet 360, no. 9331 (2002): 473–482.
5. D.N. Lakdawalla, D.P. Goldman, and B. Shang, “The Health
and Cost Consequences of Obesity among the Future Elderly,” Health
Affairs, 26 September 2006, content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.r30.
6. K.M. Flegal et al., “Excess Deaths Associated with
Underweight, Overweight, and Obesity,” Journal of the American Medical
Association 293, no. 15 (2005): 1861–1867; and D.B. Allison et al.,
“Annual Deaths Attributable to Obesity in the United States,” Journal
of the American Medical Association 282, no. 16 (1999): 1530–1538.
7. A.H. Mokdad et al., “Actual Causes of Death in the
United States, 2000,” Journal of the American Medical Association
291, no. 10 (2004): 1238–1245.
8. E.W. Gregg et al., “Secular Trends in Cardiovascular
Disease Risk Factors According to Body Mass Index in U.S. Adults,” Journal
of the American Medical Association 293, no. 15 (2005): 1868–1874.
9. Ibid., 1873.
10. C.L. Ogden et al., “Prevalence and Trends in Overweight
among U.S. Children and Adolescents, 1999–2000,” Journal of
the American Medical Association 288, no. 14 (2002): 1728–1732.
11. D.S. Ludwig and C.B. Ebbeling, “Type 2 Diabetes Mellitus
in Children: Primary Cary and Public Health Considerations,” Journal
of the American Medical Association 286, no. 12 (2001): 1427–1430.
12. S.J. Olshansky et al., “A Potential Decline in Life
Expectancy in the United States in the Twenty-first Century,” New
England Journal of Medicine 352, no. 11 (2005): 1138–1145.
S. Jay Olshansky (sjayo{at}uic.edu) is a professor
at the School of Public Health, University of Illinois at Chicago, and a research
associate at the Center on Aging, University of Chicago, and the London School
of Hygiene and Tropical Medicine.
Access
the table of contents for this package
DOI: 10.1377/hlthaff.W5.R86
©2005 Project HOPE–The People-to-People Health
Foundation, Inc.
|